DK1187635T3 - Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist - Google Patents

Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist

Info

Publication number
DK1187635T3
DK1187635T3 DK00940519T DK00940519T DK1187635T3 DK 1187635 T3 DK1187635 T3 DK 1187635T3 DK 00940519 T DK00940519 T DK 00940519T DK 00940519 T DK00940519 T DK 00940519T DK 1187635 T3 DK1187635 T3 DK 1187635T3
Authority
DK
Denmark
Prior art keywords
alpha
adrenergic agonist
nmda antagonist
anesthetic formulation
formulation
Prior art date
Application number
DK00940519T
Other languages
English (en)
Inventor
Nicholas Peter Imperial Franks
Mervyn Imperial Coll Scho Maze
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10855216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1187635(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Application granted granted Critical
Publication of DK1187635T3 publication Critical patent/DK1187635T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK00940519T 1999-06-11 2000-06-09 Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist DK1187635T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9913677.2A GB9913677D0 (en) 1999-06-11 1999-06-11 Formulation
PCT/GB2000/002271 WO2000076545A1 (en) 1999-06-11 2000-06-09 Anaesthetic formulation comprising an nmda-antagonist and an alpha-2 adrenergic agonist

Publications (1)

Publication Number Publication Date
DK1187635T3 true DK1187635T3 (da) 2004-06-21

Family

ID=10855216

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00940519T DK1187635T3 (da) 1999-06-11 2000-06-09 Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist

Country Status (14)

Country Link
US (1) US6562855B1 (da)
EP (1) EP1187635B1 (da)
JP (1) JP2003529541A (da)
AT (1) ATE259658T1 (da)
AU (1) AU778671B2 (da)
CA (1) CA2376916C (da)
DE (1) DE60008374T2 (da)
DK (1) DK1187635T3 (da)
ES (1) ES2215678T3 (da)
GB (2) GB9913677D0 (da)
PT (1) PT1187635E (da)
RU (1) RU2244558C2 (da)
WO (1) WO2000076545A1 (da)
ZA (1) ZA200110116B (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
GB0209998D0 (en) 2002-05-01 2002-06-12 Protexeon Ltd Use
CN1668315A (zh) 2002-06-12 2005-09-14 梅瑟·格里斯海姆有限公司 使用含氙气体进行脑保护
JP2006508040A (ja) * 2002-07-05 2006-03-09 メツサー グリースハイム ゲゼルシヤフト ミツト ベシユレンクテル ハフツング キセノンを含有するアジュバント
WO2004052337A2 (de) * 2002-12-06 2004-06-24 Michael Georgieff Nasale pharmazeutische präparation enthaltend eine lipophile flüssige oder gasförmige wirksubstanz
BRPI0415616A (pt) * 2003-10-21 2006-12-12 Aga Ab uso do xenÈnio para a prevenção da morte programada da célula
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
US20100022574A1 (en) * 2008-07-28 2010-01-28 EndogenX, Inc. Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
HRP20141047T1 (hr) 2008-08-01 2015-01-02 Eye Therapies Llc Pripravci za sužavanje krvnih žila i metode njihove uporabe
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20110244058A1 (en) * 2008-08-01 2011-10-06 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
SG175979A1 (en) * 2009-05-15 2011-12-29 Recro Pharma Inc Sublingual dexmedetomidine compositions and methods of use thereof
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US20110152271A1 (en) * 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
US20130072532A1 (en) * 2010-01-08 2013-03-21 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
EP2558101A4 (en) * 2010-04-15 2013-09-18 Univ Mcgill TOPICAL TREATMENTS OF PAIN
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013090278A2 (en) 2011-12-11 2013-06-20 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
JP6625966B2 (ja) 2013-03-15 2019-12-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 希ガスが豊富な液体ならびにその調製及び使用の方法
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
KR101948779B1 (ko) 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
RU2557882C1 (ru) * 2014-07-08 2015-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Способ проведения премедикации при плановом хирургическом лечении
WO2017139382A1 (en) * 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
BR112019006955A2 (pt) 2016-10-31 2019-07-02 Teikoku Pharma Usa Inc métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
US12599625B2 (en) 2021-05-13 2026-04-14 Penland Foundation Treatment of ARDS and other conditions caused by acutely elevated cytokine levels and post ARDS chronic cytokine production using inhaled anesthetics
WO2023287726A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of cancer using botulinum toxin and nitrous oxide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859685A (en) * 1986-08-13 1989-08-22 Boc, Inc. Anesthetic composition and method of using the same
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
DE69634489T2 (de) 1995-11-13 2006-02-16 Commissariat à l'Energie Atomique Adenovirus dodekahedrischer proteinkomplex, dieser enthaltende zusammensetzung und verwendungen davon
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
FR2787713A1 (fr) 1998-12-23 2000-06-30 Johan Huysman Composition en tant que medicament et utilisation d'une telle composition pour l'obtention d'un medicament destine a l'anesthesie, notamment medicament analgesique
DE19910986C2 (de) 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist

Also Published As

Publication number Publication date
DE60008374D1 (de) 2004-03-25
AU5544400A (en) 2001-01-02
GB0014165D0 (en) 2000-08-02
EP1187635A1 (en) 2002-03-20
AU778671B2 (en) 2004-12-16
GB9913677D0 (en) 1999-08-11
EP1187635B1 (en) 2004-02-18
DE60008374T2 (de) 2004-12-09
GB2352633B (en) 2002-04-17
ZA200110116B (en) 2003-07-23
CA2376916C (en) 2010-09-21
WO2000076545A1 (en) 2000-12-21
JP2003529541A (ja) 2003-10-07
RU2244558C2 (ru) 2005-01-20
ATE259658T1 (de) 2004-03-15
ES2215678T3 (es) 2004-10-16
US6562855B1 (en) 2003-05-13
GB2352633A (en) 2001-02-07
PT1187635E (pt) 2004-07-30
CA2376916A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
DK1187635T3 (da) Anæstetisk formulering der omfatter en NMDA-antagonist og en alfa-2 adrenerg agonist
MA27265A1 (fr) Formulations d'agoniste opioide a antagoniste liberable et sequestre
NO20024309D0 (no) Intradermal penetreringsmidler for topikal lokal anestetisk administrering
EE9700192A (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja antatsiidainet või alginaati
AU5984801A (en) Local anesthetic methods and kits
EE9700195A (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja prokineetilist ainet
EE9700194A (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja NSAID
DE60044041D1 (de) Exendine zur Glucagon Suppression
DE60216078D1 (de) Opioid enthaltende arzneiform gegen missbrauch
DK1191926T3 (da) Ny omeprazol- og (S)-omeprazolformulering
CY1115869T1 (el) Χρηση ανταγωνιστων του υποδοχεα τυπου 1 της αγγειοτενσινης ii για την προληψη του διαβητη
EA199700230A1 (ru) Дозирующий ингалятор для дипропионата беклометазона
MY129356A (en) Electrospun pharmaceutical compositions
GEP20074047B (en) Pramipexole once-daily dosage form
GEP20063996B (en) Aripiprazole complex formulation and use thereof
ES2157881T3 (es) Metanosulfonato de paroxetina.
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
MY141012A (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
NO20010537D0 (no) Farmasöytiske preparater omfattende ibuprofen og domperidon
ATE297760T1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
CY1108502T1 (el) Ελεγχομενης-αποδεσμευσης συνθεσεις οι οποιες περιεχουν οπιοειδη αγωνιστη και ανταγωνιστη
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
MXPA04001878A (es) Composiciones medicinales que comprenden antagonista del receptor de angiotensina ii.
AU2002235767A1 (en) Novel pharmaceutical compositions based on anticholinergic agents and dopamine agonists
DK1408943T3 (da) Lægemiddelformulering indeholdende en LTB4 antagonist og et befugtningsmiddel